How it started
History
John Kapoor is not the founder but has been a major shareholder since the 1990s.
Akorn acquired rival Hi-Tech Pharmacal in 2013.
In June 2015, it was reported that a hacker was trying to sell an Akorn customer database of more than 50,000 records. Akorn commented that "Although much of the information acquired is publicly available, we are in the process of notifying our valued customers about this incident".
In April 2017, Akorn agreed to be acquired by Fresenius for $4.3 billion. These plans were abandoned by Fresenius after Akorn couldn't meet basic requirements for an acquisition.
In October 2018, Akorn received Abbreviated New Drug Application approval from the Food and Drug Administration for Bimatoprost Ophthalmic Solution, 0.03%.
From Wikipedia’s article on Akorn, shared under CC BY-SA 4.0.3